Charcot-Marie-Tooth disease (CMT) was the focus of the second edition of a European congress held in Antwerp on 23, 24 and 25 October 2025, bringing together nearly 140 researchers, doctors, patients and representatives of the pharmaceutical industry:
- The recently founded European Charcot-Marie-Tooth Research Association (ECRA) elected its first official board, comprising scientists, doctors and patient representatives, to coordinate European efforts and involve industry in the development of new treatments.
- Significant advances were presented, such as long-read sequencing to improve genetic diagnosis and the identification of new genes linked to CMT.
- Several promising therapeutic avenues were discussed (ongoing clinical trials, gene and cell therapy, pharmacology, etc.).
- New technologies — accelerometers, digital applications, telemedicine and virtual reality, etc. — offer new ways of organising medical follow-up, even remotely, involving patients in rehabilitation and evaluating drug candidates.
2nd European CMT Specialist Conference University of Antwerp website
Uniting Science & Community: the 2nd CMTSC ECMTF website
